Shin Poong Pharm acquires approval of its modified drug, Pyramax’

Published: 2016-05-23 12:43:32

Updated: 2016-05-23 12:46:20

Shin Poong Pharm(CEO Jae-man Yoo) announced approval of its incrementally modified drug, a child malaria treatment ‘Pyramax Gran’ having pyronaridine phosphate as a main substance from the Ministry of Food and Drug Safety.

Pyramax Gran and Pyramax Tab, products jointly developed by Shin Poong Pharm and MMV(Medicines for Malaria Venture), were tested through Phase 3 clinical trials targeting 3...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.